Quarterly report pursuant to Section 13 or 15(d)

Other Intangible Assets (Tables)

v3.19.2
Other Intangible Assets (Tables)
 6 Months Ended
Jun. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Identifiable Intangible Assets Carrying Value

The net carrying value of the identifiable intangible assets as of June 30, 2019 and December 31, 2018 are as follows:

 

          As of June 30, 2019     As of December 31, 2018  
          (unaudited)        
    Life     Carrying     Carrying  
    (Years)     Amount     Amount  
                   
Asuragen acquisition:                        
Thyroid     9     $ 8,519     $ 8,519  
RedPath acquisition:                        
Pancreas test     7       16,141       16,141  
Barrett’s test     9       18,351       18,351  
Total           $ 43,011     $ 43,011  
                         
CLIA Lab     2.3     $ 609     $ 609  
                         
Accumulated Amortization           $ (15,393 )   $ (13,767 )
                         
Net Carrying Value           $ 28,227     $ 29,853  

Schedule of Future Estimated Amortization Expense

Estimated amortization expense for the next five years is as follows, based on current assumptions of future product launches:

 

2019     2020     2021     2022     2023  
$ 3,252     $ 4,272     $ 4,908     $ 2,987     $ 2,987